Navigation Links
Japanese Cancer Patients Will Have Access to Compensator-Based IMRT with Opening of .decimal, Inc. Office in Tokyo and Hiring of Key Personnel
Date:11/4/2009

SANFORD, Fla., April 13 /PRNewswire/ -- .decimal, Inc., leading manufacturer of patient-specific medical devices, opens their first international office in Tokyo, Japan. An office in Japan will further strengthen .decimal's commitment to the Japanese market.

(Logo: http://www.newscom.com/cgi-bin/prnh/20090203/CLTU104LOGO )

Richard Sweat, President/CEO of .decimal said, "The opening of an office in Japan is another example of our dedication to provide cancer patients around the world with innovative treatment solutions."

Japan is the second largest market in the world for medical devices and has a $20 billion medical device industry, with $5 billion in U.S. imports, according to the International Trade Administration. With an increasing number of patients with chronic diseases in Japan, medical devices to treat age-related diseases shows the potential for steady growth.

"After visiting Japan, meeting with medical universities and doctors and reviewing our market research, it was evident which market would be the next opportunity for us to grow globally. It is our understanding that there are over 700 radiation therapy centers and more than 1,000 full-time medical doctors in Japan - a substantial statistic," said Mark Mills, Senior Vice President of Sales and Marketing for .decimal. "We are excited to bring our products to market in Japan and we believe an authorized office is the appropriate next step."

.decimal will be providing cancer institutions in Japan the devices necessary to deliver compensator-based Intensity Modulated Radiation Therapy, an advanced form for delivering radiation. Compensators provide the maximum dose to the tumor, while providing maximum protection to the surrounding healthy tissues and organs, reducing the risk of acute and chronic damage. .decimal is in the process of being cleared by Japanese regulatory agencies and looks forward to begin offering their products commercially overseas.

"Cancer centers in Japan will soon have the opportunity to enhance their current radiation delivery capabilities through our unique pay-as-you-go, Internet-based manufacturing business model," said Sweat.

.decimal will be represented in Japan by Sam Tabuchi of Enterprise Florida-Japan. The .decimal office will be located at:

    Sagamiya #2 Building 5F
    10 Ichibancho
    Chiyoda-ku, Tokyo 102-0082
    Phone: 03-3230-0505

.decimal is a medical device manufacturer of patient-specific devices, including missing tissue compensators, modulators for advanced IMRT delivery, as well as apertures and range compensators used in proton therapy. The company has been providing radiation therapy products for over twenty years and serves more than 200 customers. For more information concerning .decimal, please see its Web site at www.dotdecimal.com.

SOURCE .decimal, Inc.


'/>"/>
SOURCE .decimal, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. BioMarin Partner AnGes MG, Inc. Submits BLA to Japanese Ministry of Health
2. Sarasotas Roskamp Institute Highlights Positive Japanese Data that Validates its Ongoing Alzheimers Disease Research
3. Data Presented at Annual Meeting of Japanese Society of Interventional Cardiology Demonstrate OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) Has Better Outcomes When Compared to Drug-Eluting Stents
4. Alexion Reports Positive Results from AEGIS Registration Study of Soliris in Japanese Patients With PNH
5. The Japanese Cancer Association and Debiopharm Group Present the JCA-Mauvernay Award to Dr Ushijima for his Oncology Research
6. BioWa Announces Second Japanese License of POTELLIGENT(R) Technology to Otsuka Pharmaceutical
7. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
8. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
9. Indevus Receives Approvable Letter From FDA for VALSTAR(R) for Bladder Cancer Therapy
10. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... 4, 2017  South Korean-based healthcare product Development Company ... "cprCUBE" on Kickstarter. The device will educate the user ... with better efficiency compared to the dated and pricey ... on efficacy of the compression for a more informed ... goal to raise $5,000. ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that ... insurance companies have a waiver for care if the client has a cognitive impairment ... family pays for care, is often waived, so the benefits from their insurance start ...
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The ... the most popular and least understood books in the Holy Scriptures, Revelation. The Book ... have baffled scholars for centuries. Many have tossed it off as mere rubbish, but ...
(Date:10/13/2017)... ... ... On The Brink”: the Christian history of the United States and the loss of ... William Nowers. Captain Nowers and his wife, Millie, have six children, ten grandchildren, ... Navy. Following his career as a naval aviator and carrier pilot, he spent ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed ... consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has ... highest standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information ... we intend to develop to enable prevention of a major side effect of ... loss, especially in pediatric patients. For cisplatin, hearing loss is FDA listed on-label ...
Breaking Medicine News(10 mins):